SOM Biotech announces the database lock of its Phase2b study with SOM3355 in Huntington’s chorea patients and looks for top-line results in August.

posted on July 25, 2024

SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, is pleased to announce the database lock of the Phase 2b study SOMCT03 with SOM3355 for the treatment of chorea in Huntington’s Disease.